Lupus patients get custom steroid tapering plan in new study

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient aged ≥ 6 years * Patient who met the American College of Rheumatology criteria (ACR) or the Systemic Lupus International Collaborating Clinics Classification (SLICC) for systemic lupus erythematosus. * Patients needs (re)initiation of oral prednisone regimen at least at 0.5 mg/Kg/d(or \>30mg/d for patients \>60 kg) in combination with mycophenolate mofetyl or mycofenolic acid or cyclophosphamide at usual dose including : i) patient who receives bolus of methylprednisolone the week before and/or the week after inclusion for treating the lupus flare ii) patient who was previously treated by a low-prednisone dose (≤ 7.5 mg/d in patients ≥ 60 kg and ≤ 0.1 mg/kd/d in patient \< 60 kg). iii) patient who was previously treated by prednisone ≥ 0,5 mg/kg/d (or \>30mg/d for patients \>60 kg) but stopped since at least one month before inclusion * Patient with stable doses of other immunosuppressive or biological drugs before inclusion (at least 15 days for Imurel, Methotrexate, Tacrolimus ; at least 6 months for Rituximab, Belimumab) and during the 3 months of patient participation in the study. * Signed informed consent form by the patient (if aged ≥ 18 years), or by the parents / legal guardian and patient's agreement (if aged \< 18 years) * Patient affiliated to the health insurance system Exclusion Criteria: * Patient presents contraindications to corticosteroids * Patient presents contraindications to MMF, mycofenolic acid or cyclophosphamide for patient receiving immunosupressor * Patient cannot be treated by oral way * Patient whose physician has planned to stop prednisone in less than 3 months * Patient (or parents for minor) are unable to give a written informed consent for physical or psychical reasons * Patient disagrees with the study